Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 30;10:1493. doi: 10.1038/s41598-020-58438-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Afatinib and YM155 reduce PDX mammary tumor growth in vivo. HCI01 PDX cells were injected into the mammary fat pads of NSG mice. After 12 days of tumor growth, mice were divided into four groups (n = 3 mice per group): untreated, afatinib (25 mg/kg, daily oral gavage for 7 days), YM155 (5 mg/kg, 7-day continuous subcutaneous infusion via Alzet pump), and afatinib + YM155 (same doses and routes of administration as monotherapy groups). (a) Tumor area (length x width) over time for each treatment group, monitored via caliper measurements. The treatment period is indicated by red dotted lines. Error bars represent standard deviation. Significance is shown only for endpoint measurements (*p < 0.05, **p < 0.01); p-values for all timepoints are listed in Supplementary Table S5. (b) Mouse weights over time for each treatment group. The treatment period is indicated by red dotted lines. (c) Tumor weights for each treatment group, obtained after tumor removal at the study endpoint; ***p < 0.001; p-values are listed in Supplementary Table S5. (d) Photographs of mammary tumors for each treatment group at the study endpoint; ruler scale is mm.